Conferences
ESMO 2024: Prospective Randomized Phase II Trial of Ipilimumab + Nivolumab Versus Standard of Care in Non-Clear Cell RCC: Results of the SUNNIFORECAST Trial
September 13, 2024
ESMO 2024: Final Analysis of the Phase 3 LITESPARK-005 Study of Belzutifan Versus Everolimus in Participants with Previously Treated Advanced Clear Cell RCC
September 13, 2024
Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024
September 11, 2024
AVEO Oncology, an LG Chem company, Announces Acceptance of Late-Breaking Oral Presentation of TiNivo-2 Results at ESMO 2024
September 6, 2024
ESMO 2024: Bayer to Present New Prostate Cancer Data and Continued Oncology Portfolio Research at ESMO 2024
September 6, 2024
WCET 2024: Xi and SP Nephroureterectomy and Bladder Cuff
August 15, 2024
WCET 2024: Leave No Stone Unmeasured: A Comparison of Three Methods for Determining Stone Volume
August 15, 2024
WCET 2024: Panel: How to Manage Multiple Small Renal Masses
August 15, 2024
WCET 2024: What's Next in Urologic Robotics: Future Perspectives
August 15, 2024
WCET 2024: Panel: New Approaches for Stone Retrieval
August 14, 2024